NP / PA
Resch, Kayla
Resch, Kayla was paid $310K by Medicaid between Mar 2020 and Dec 2024, across 16 billing codes. Its largest line is 99203, doctor's office visit, new patient (routine) — 28% of everything it billed.
33Billing provider infoRESCH, KAYLA
WARWICK, RI 02886
WARWICK, RI 02886
33aNPI1083265003assigned 09/20/2019
33bProvider typePhysician Assistant
28Total paid$310K
24GClaims4,147
24DCodes billed16
24AFirst – last monthMar 2020 – Dec 2024
Compared with peers
Next to other Physician Assistant providers in Rhode Island
Rank by total paid#13 of 215
Median peer was paid$17K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 609 | $31K | |
| 2021 | 1,212 | $95K | |
| 2022 | 1,138 | $98K | |
| 2023 | 812 | $63K | |
| 2024incomplete | 376 | $24K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 28% | 694 | 590 | $88K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 22% | 738 | 644 | $68K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20% | 459 | 454 | $63K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 7.6% | 574 | 481 | $23K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.8% | 406 | 402 | $15K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4.4% | 312 | 299 | $14K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.3% | 125 | 122 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.3% | 289 | 253 | $7K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.1% | 102 | 100 | $7K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 54 | 54 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 72 | 72 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 172 | 102 | $2K |
4 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.